The endothelium plays a central role in modulating vascular homeostasis, responding to physical and chemical signals by production of a wide range of factors that regulate vascular tone, cellular adhesion, thromboresistance, cell proliferation and vessel wall inflammation. In normal vascular physiology, endothelial cells maintain the vascular wall in a quiescent state by inhibition of inflammation, cellular proliferation, and thrombosis. When exposed to cardiovascular risk factors or, more generally, altered chemical and physical signals, they adopt a pro-atherosclerotic phenotype, characterised mainly by an increased secretion of substances with vasoconstricting, prothrombotic, proliferative and proinflammatory properties. 1 At the microvascular level, this might lead to local dysregulation of the blood flow, potentially activating angiogenetic pathways that might result in the formation of new small vessels. 2 Because of its central role in the neoangiogenesis and in the regulation of local blood flow, endothelial dysfunction and the disarray of newly formed vessels within the neoplastic mass are thought to play a key role in the abnormal intratumoral perfusion, leading to local hypoxia, impaired permeability, extracellular matrix degradation and efflux of cancer cells that ultimately result in a greater risk of metastatic diffusion 3 (Figure 1 ). The key role of endothelial cells in regulating tumour physiology, including growth and dissemination, is confirmed by the results of clinical trials documenting a positive impact on cancer prognosis of novel antineoplastic agents that inhibits endothelial cell proliferation. 4, 5 In this issue of the European Journal of Preventive Cardiology, Toya et al. explore the prospective association between endothelial function, measured at the level of the microcirculation, and future risk of developing solid-tumour cancer. 6 The authors enrolled a population of 687 patients who attended the Mayo Clinic for the assessment of chest pain and/or cardiovascular risk. The reactive hyperaemia peripheral arterial tonometry (RH-PAT) index was used to assess the presence of baseline microvascular endothelial dysfunction (MED), while blood tests and clinical history were collected to define the overall cardiovascular risk of the patients and the pre-existing presence of solid-tumour cancers. Following a median follow-up of six years, the authors assessed how many patients received a diagnosis of solid-tumour cancers, relating this information with the baseline presence of MED, defined as an RH-PAT index 2.0. At baseline, patients with MED had a much higher cardiovascular risk factor burden than patients without MED. The presence of MED at baseline, age and male sex were associated with an increased incidence of solid-tumour cancer during follow-up, and individuals with MED had a lower solid tumour cancer-free survival compared with individuals without MED. The association between MED and the risk of solid-tumour cancer remained significant even after adjustment for common cardiovascular risk factors and history of coronary artery disease. Based on these observations, the authors concluded that abnormal microvascular endothelial function may not only be considered a marker of future risk of cardiovascular disease but may also become a surrogate marker of the future cancer risk. 6 The merit of this study is to explore a potential mechanism explaining the link between cardiovascular diseases and a higher incidence of cancer that has been suggested in previous observational studies and clinical trials. [7] [8] [9] Particularly, the recent results obtained in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) suggests that an antiinflammatory treatment against interleukin (IL)-1b is able to improve cardiovascular outcome, as well as to reduce the incidence and mortality for cancer. 10 The pathophysiological alterations underpinning the relationship between MED and incidence of cancer remain to be fully elucidated. While endothelial dysfunction might contribute to the creation of a prooncogenic environment, the relatively short follow-up of the current study makes more likely that the increased incidence of cancer in patients with MED might be related to a reduced rate of progression, invasiveness and metastatic spread of neoplastic mass that were prevalent but undiagnosed at trial entry.
Because of its anatomical location, the endothelium is optimally placed to influence tissue biology. Following activation, endothelial cells produce a large number of vasoactive molecules, free radical species and proinflammatory cytokines that might disrupt the local and distal vascular wall homeostasis, influencing blood perfusion and extravascular signalling. 1 The capacity of endothelial cell function to modify the biology of parenchymal cells through regulation of the blood flow and reciprocal signalling exchange supports the hypothesis that dysfunctional endothelial cells might contribute to cancer evolution. 11 For example, the early seminal work conducted by the research group of Professor Libby has documented that the acquisition of a dysfunctional phenotype by endothelial cells following incubation with IL-1a can induce production of increasing amounts of IL-1b by the same cells. 12 Given that this vicious cycle does not involve only endothelial cells but might extend to the other components of the vascular wall, 13 the first proinflammatory signal received and transmitted by the endothelium might be amplified several times before reaching the surrounding parenchymal tissue (Figure 1 ). This might be relevant for cancer growth, invasiveness and metastatic dissemination, as high concentrations of inflammatory cytokines within the tumour microenvironment can promote angiogenesis and tumour growth 14 ( Figure  1 ). Furthermore, the rapid and disorganised growth of a neoplastic mass leads to local hypoxia that, in turn, activates the production of a large amount of MMP-2 (Type IV collagenase) by endothelial cells, 15 ultimately promoting tissue destruction and, potentially, metastatic dissemination (Figure 1 ). Another important merit of the study from Toya and colleagues is the assessment of microvascular rather than Figure 1 . Endothelial function as a key regulator of vascular and cancer homeostasis. Endothelium responds to physical and chemical signals by production of a wide range of factors that regulate vascular tone (nitric oxide (NO)), cellular adhesion (vascular cell adhesion protein (VCAM)), cell proliferation (vascular endothelial growth factor (VEGF)) and vessel wall inflammation (interleukin (IL)-1b, IL-6). In normal vascular physiology, endothelial cells maintain the vascular wall in a quiescent state. When exposed to cardiovascular risk factors (hypertension, diabetes mellitus, smoking) or, more generally, altered signals leading to reactive oxygen species (ROS) production, they adopt a pro-atherosclerotic phenotype. The activated endothelium promotes vasoconstriction, thrombosis, cell proliferation, vascular wall infiltration and secretion of proteolytic by molecules which are key pathways involved in the initiation and progression of the atherosclerosis. Similar pathways, however, are thought to be involved in tumour progression by promoting neoangiogenesis, proliferation and diffusion of neoplastic cells. macrovascular endothelial function. Indeed, the microcirculation represents the key network that regulates local blood perfusion and accounts for most of the blood-tissue exchanges. Thus, a dysregulation of the endothelial cell function at this level might have direct impact on tissue perfusion, metabolism and biology. Despite these strengths, some limitations should be recognised. First, the authors did not report validated measures of inflammatory markers known to be related to the cardiovascular and cancer risk (i.e. IL-1b, IL-6 or C-reactive protein). Similarly, markers of oxidative stress, endothelial cell injury or angiogenic capacity (i.e. vascular endothelial growth factor (VEGF)) were not measured, making the interpretation of the results more difficult and speculative. The lack of a detailed assessment of the presence/absence of cancer at baseline using imaging techniques makes reverse causality possible, as people with impaired endothelial function at baseline might represent those with prevalent but undiagnosed cancer at study entry. Furthermore, a limited number of patients developed cancer during follow-up, requiring confirmation of the results in larger and longer prospective studies. The capacity of the RH-PAT index to provide accurate information on endothelial function remains a matter of debate. While the same group of authors documented that endothelial function assessed by non-invasive peripheral arterial tonometry is able to predict late cardiovascular adverse events, 16 two large cross-sectional studies 17, 18 showed modest associations between flowmediated dilation (considered the gold standard method for the peripheral assessment of endothelial function) and the signals obtained with peripheral arterial tonometry. This might reflect the different physiology regulating microvascular and macrovascular endothelial function but might also suggest that these two methodologies could measure different aspects of the vascular biology. Finally, the authors focused their analyses on the risk of solid-tumour cancers, while the discovery of clonal haematopoiesis of indeterminate potential supports a stronger pathophysiological relationship between haematologic malignancies and risk of cardiovascular disease. 19 In conclusion, the paper by Toya et al. provides evidence of potential mechanisms accounting for the increased incidence of cancer observed in patients at risk of or with established cardiovascular disease. While the low number of patients and the relatively short period of observation require validation of the data in larger and longer follow-up studies, pathophysiological mechanisms might explain the observed association between MED and greater risk of a clinical diagnosis of cancer during follow-up. Among these, vascular inflammation and disarray of newly formed vessels are likely to represent central factors influencing the increased risk of cancer growth and diffusion in people with MED. This hypothesis should be tested in future studies that have the availability of circulating markers of endothelial cell activation/proliferation, including MMP and VEGF, to assess which specific aspect of endothelial cell biology/function is more likely to account for the relationship between MED and the risk of cancer diagnosis.
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